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Available online at www.sciencedirect.comThrombocytopenia with absent radii (TAR) syndrome is a rare
disorder combining specific skeletal abnormalities with a
reduced platelet count. Rare proximal microdeletions of 1q21.1
are found in the majority of patients but are also found in
unaffected parents. Recently it was shown that TAR syndrome
is caused by the compound inheritance of a low-frequency
noncoding SNP and a rare null allele in RBM8A, a gene
encoding the exon-junction complex subunit member Y14
located in the deleted region. This finding provides new insight
into the complex inheritance pattern and new clues to the
molecular mechanisms underlying TAR syndrome. We discuss
TAR syndrome in the context of abnormal phenotypes
associated with proximal and distal 1q21.1 microdeletion and
microduplications with incomplete penetrance and variable
expressivity.
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Clinical features
Thrombocytopenia with absent radii (TAR) syndrome is
characterized by a reduction in the number of platelets
(the cells that make the blood clot) (generally below
50  109 L1, normal range 150–350  109 L1) and
the absence of one of the bones in the forearm (the
radius) but with preservation of the thumb.
TAR syndrome was first described by Gross et al. [1] and
Shaw and Oliver in 1959 [2], but Judith Hall was the first
to define it as a syndrome in 1969, presenting clinical
Open access under CC BY-NC-ND license.Current Opinion in Genetics & Development 2013, 23:316–323 findings in a cohort of 40 patients [3]. The presence of the
thumbs distinguishes TAR from other syndromes that
combine blood abnormalities with absence of the radius,
such as Fanconi anemia [3–5]. The severity of skeletal
abnormalities varies from absence of radii to virtual
absence of upper limbs (phocomelia) with or without
lower limb defects, such as malformations of the hip
and knee [3,5]. TAR cases have low numbers of mega-
karyocytes, the platelet precursor cells that reside in the
bone marrow, and cases frequently present with bleeding
episodes in the first year of life [3,5]. A remarkable feature
of TAR syndrome is that the platelet count can improve
with age and bleeding diminishes [5]. Other symptoms
have been described in a series of 34 TAR patients [6],
with renal anomalies and cardiac anomalies in respect-
ively 23% and 15% of patients, and 47% suffering from
intolerance to cow’s milk.
Genetic mechanism
TAR syndrome has an incidence of approximately 1 in
240 000 births [7] and was thought to be inherited as an
autosomal recessive disease [8] based on finding affected
siblings. There is however no clear evidence of increased
incidence in consanguineous families with only one case
reported [9]. On the other hand, vertical parent-to-child
transmission has been reported [10], as well as the case of
a male patient and maternal uncle [11]. This unusual
inheritance pattern has complicated the application of
classic linkage analysis methods and homozygosity map-
ping approaches. Initial attempts to resolve the genetic
basis of TAR syndrome have therefore consisted mainly
of candidate gene studies [12,13] and identification of
abnormal karyotypes [6]. Stripploi et al. [13] failed to
identify mutations in c-mpl, the receptor for thrombo-
poietin, the principal cytokine regulating platelet pro-
duction. No mutations were identified either in HoxA10,
HoxA11, and Hox12 [12] even though HoxA11 has been
associated with amegakaryocytic thrombocytopenia [14].
In 2007 Klopocki et al. [15] identified proximal micro-
deletions of 1q21.1 in all of 30 TAR patients tested. The
deletion was inherited paternally in 5 cases and mater-
nally in 12 cases and occurred de novo in a further 5 cases
[15]. The deletion is rare but segregates in the popu-
lation: it was observed twice in a set of 8329 unaffected
adult controls [16]. The parents of TAR patients who
carried the microdeletion were unaffected. The authors
therefore suggested that the deletion was required butwww.sciencedirect.com
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Compound inheritance of a low-frequency noncoding SNP and a rare null mutation in RBM8A causes TAR syndrome. The gray box shows the two
noncoding SNPs in respectively the 50UTR (chr1: 145 507 646 G/A, hg19) and the first intron (chr1: 145 507 765 G/C, hg19) of RBM8A that were
identified in a series of 55 TAR cases analyzed by Albers et al. [17]. The minor allele frequency (MAF) of each SNP is indicated below each variant.
One of these two noncoding SNPs was present with either a rare proximal 1q21.1 deletion (see also Figure 3), or a novel loss-of-function mutation
(frameshift insertion or nonsense mutation) in RBM8A in 53 TAR cases. The four inheritance patterns and the corresponding number of cases that were
observed in Ref. [17] are shown below the gene.not sufficient to explain TAR and that a second causative
allele (sometimes described as a modifier) must exist.
They sequenced the protein coding sequence of 10 genes
in the 200 kb region that was deleted in all 30 patients,
but no mutations were identified.
Low-frequency noncoding SNPs in RBM8A
In order to identify the second causative allele, we used
high-throughput sequencing of DNA enriched for
protein-coding genes (exome-sequencing) in five unre-
lated TAR cases with a 1q21.1 deletion [17]. Assum-
ing autosomal recessive inheritance, we hypothesized
that the second causative allele would most likely be
located in the 200 kb minimal deleted region identified
by Klopocki et al. However, we also could not identify
any rare deleterious protein-coding variants in the same
gene in all five cases. We then considered all low-
frequency variants (<5%) in the minimal deleted
region, regardless of their predicted consequences, as
potentially causative. This allowed us to identify a low-
frequency SNP (allele frequency 3%) in the 50UTR
region of the gene RBM8A in four of the TAR cases
sequenced and a low-frequency SNP (allele frequencywww.sciencedirect.com 0.4%) in the first intron of the same gene in the last case
(Figure 1). The frequency of the TAR deletion (1/8329,
Ref. [16]) and the frequency of two noncoding SNPs
are roughly consistent with the incidence of 1:240 000
reported in Ref. [7]. In principle, the technique of
exome-sequencing is focused on enriching for exonic
regions. However, due to partial overlaps with the
hybridization probes and capture design to enable
detection of intronic splice site mutations, it is often
possible to call sequence variants within 50 bp of the
targeted regions. This allowed us to identify both the
50UTR SNP and the intronic SNP from the targeted
resequencing of exons.
The findings were confirmed by Sanger sequencing in a
further 48 individuals with TAR and a 1q21.1 deletion,
with co-inheritance of the 50UTR SNP in 35 cases and the
intronic SNP in a further 11. Crucially, an additional two
patients who did not have the deletion but carried the
50UTR SNP were found to carry a loss of function
mutation on the other RBM8A allele (frame shift insertion
and premature termination codon). From these data we
concluded that it is the compound (bi-allelic) inheritanceCurrent Opinion in Genetics & Development 2013, 23:316–323
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The noncoding SNPs found in TAR cases are located in regulatory elements in megakaryocytes, the precursor cells of platelets. Sequencing of RNA
from cord-blood-derived megakaryocytes showing that RBM8A is expressed in megakaryocytes. Histone modifications from the ENCODE Project [59]
in seven cell lines (GM12878, H1-hESC, HSMM, HUVEC, K562, NHEK, and NHLF) indicate the presence of regulatory elements at the promoter and
first intron of RBM8A. H3K4Me1 is often found near regulatory elements, H3K4Me3 is often found near promoters and H3K27Ac is often found near
active regulatory elements (UCSC Genome Browser). FAIRE marking regions of open chromatin showing that the 50UTR SNP and first intron SNP are
accessible to DNA binding proteins in megakaryocytes. Computational modeling predicted that the 50UTR SNP minor allele creates a binding site for
the transcription factor Evi1, a transcriptional repressor. It was shown that in vitro the minor allele of the 50UTR shows increased binding of Evi1 [17].
Thus, epigenetic annotation facilitates interpretation of sequence variants in nonprotein-coding sequence.of a noncoding SNP together with a null mutation in
RBM8A that causes TAR syndrome.
A number of unaffected parents were found to be
homozygous for the 50UTR SNP, demonstrating that
being homozygous for one of the two regulatory var-
iants is not sufficient to cause TAR syndrome. The two
noncoding TAR SNPs are present at low frequency in
European population, but were not detected in African
populations in Phase 1 of the 1000 Genomes Project
[18]. There have been reports of TAR in the Nigerian
population [19], and it would therefore be interesting to
see if the mechanism of inheritance and sequence
variants in RBM8A described above explain TAR in
that population as well.
Reduced expression of Y14, the protein
encoded by RBM8A, in TAR patients
The two noncoding variants are located in regulatory
elements in megakaryocytes, the precursor cell of platelets
(Figure 2) [17]. The level of Y14, the protein encoded by
RBM8A, was found to be significantly lower in the plateletsCurrent Opinion in Genetics & Development 2013, 23:316–323 of TAR patients [17]. This strongly suggests that the
mechanism by which the compound inheritance of the
noncoding variant and the rare null allele causes TAR
syndrome is by reducing the expression of Y14 below a
critical threshold [17]. How this happens exactly is not
clear, and the molecular mechanism may be different for
the 50UTR SNP and the intronic SNP. In reporter assays
the minor 50UTR allele and the intronic allele led to
decreased transcription in megakaryocytic cell lines, but
not in a vascular endothelial cell line [17]. Together with
the noncoding nature of the two SNPs, this strongly
suggests tissue-dependent and possibly developmental
stage-dependent effects of the two noncoding SNPs on
RBM8A expression. The minor allele of the 50UTR SNP
was furthermore shown to result in increased binding of the
transcription factor EVI1 in vitro [17]. However, it is not
clear at this stage if EVI affects transcription by binding to
the DNA (by acting as a transcriptional repressor in com-
petition with transcription factors binding to the normal
allele), or by inhibiting translation by binding to the RNA.
For the intronic SNP, reduced protein binding to the
mutant DNA sequence was demonstrated in vitro, butwww.sciencedirect.com
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tion factor binds to this particular regulatory region of the
RBM8A gene [17].
RBM8A/Y14 is a member of the exon-junction
complex
Y14 is a small 174 aa protein with an RNA-binding
domain (Figure 1). Y14 is one of the four components
of the core exon-junction complex (EJC), which is
involved in basic cellular functions such as nuclear export
and subcellular localization of specific transcripts [20,21],
translational enhancement [22] and nonsense-mediated
RNA decay (NMD) [21,23,24]. The EJC is also associated
with splicing. It is deposited 24 nt upstream of exon–exon
junctions following pre-mRNA splicing [25]; in vivo the
majority of exon junctions carry an EJC [26]. It was
suggested that EJCs form ‘super-complexes’ with other
EJCs to promote mRNA packaging and compaction [26].
Knockdown of the Y14 ortholog tsu in Drosophila melano-
gaster results in major defects in abdomen formation [27],
and is lethal in Danio rerio [17], highlighting the critical
importance of Y14 and the EJC during embryonic de-
velopment [28].
Biological mechanisms implicated in
hematological features of TAR syndrome
What is not clear at this stage is how a deficiency in Y14
exerts its effect at a cellular level and in particular how
it affects the production of megakaryocytes and plate-
lets. Several studies have focused on the characteriz-
ation of the nature of the thrombocytopenia in TAR
patients. There are clearly a low number of megakar-
yocyte progenitors in the bone marrow in TAR patients
[5,29,30] and this also translates in vitro where mega-
karyocyte colony output is virtually absent from
patients’ bone marrow progenitors [29–31]. In contrast,
erythroid and myeloid colony growth from the TAR
infants marrow cells was preserved, which strongly
suggests a lineage specific maturation defect or a differ-
entiation blockage [31]. Several studies have therefore
focused on potential signaling defects in TAR patients
as an explanation for this observation; in particular
downstream of the main cytokine that controls mega-
karyocyte differentiation (thrombopoietin, TPO) [32–
34]. The most recent study showed defects in throm-
bopoietin signal transduction in the platelets of 12/13
pediatric patients [34]. In particular these authors
showed a correlation between the lack of phosphoryl-
ation of the Jak2 kinase (directly downstream of the
thrombopoietin receptor) and the platelet count. Inter-
estingly this defect corrected with age with 10/11 adult
samples showing normal Jak2 phosphorylation in
response to TPO [34]. At this stage, there is no clear
evidence of how a deficiency in the EJC affects mega-
karyocyte maturation and how it would have an influ-
ence on the defective cell signaling described above.www.sciencedirect.com Microdeletions and microduplications in the
1q21.1 region are associated with a variety of
phenotypes
Chromosomal region 1q21.1 is structurally complex: it
contains many segmental duplications (SDs) and the
region still contains several assembly gaps (Figure 3)
[15,35–43]. Studies of microdeletions and microdupli-
cations of 1q21.1 showed that the break points of these
structural variants tended to co-occur with these SDs
[16,40,42], suggesting that the cause of many de novo
microdeletions and microduplications in this region is
nonallelic homologous recombination [36,42,44,45]. As
an illustration of the likely impact of these repetitive
regions in 1q21.1 on the size of the deletion, the majority
(28/30) of the TAR patients studied by Klopocki et al.
carried a 500 kb deletion, and only one patient carried a
substantially smaller deletion (the ‘minimal deletion’
used to identify the noncoding TAR mutations in Ref.
[17]). Given the qPCR probes used only variations in
the distal end but not in the proximal coordinates of the
deletion were identified in that study [15].
Microdeletions and microduplications of 1q21.1 are
associated with a wide range of phenotypes. The
deletions associated with TAR syndrome are located
proximally (Figure 3). Distal 1q21.1 deletions and dupli-
cations are associated with microcephaly or macrocephaly
[40,41], schizophrenia [38,39], and a spectrum of devel-
opmental delay, neuropsychiatric abnormalities, and dys-
morphic features and congenital anomalies
[16,35,37,40,42] but are not associated with a specific
syndrome [42]. Patients with a deletion or duplication
spanning both the TAR region and the distal region have
been reported ([42]; the ‘class II’ deletions and ‘class II’
duplications in Ref. [40]), as well as patients with a
deletion in the TAR region and a duplication in the distal
region [40]. Weak evidence for proximal 1q21.1 dupli-
cations in the absence of distal duplications being dele-
terious has been reported at P = 0.03 [46] and P = 0.051
[16]. In a study of 15 767 children with intellectual dis-
ability and various congenital defects, distal deletions
were found to be most strongly associated with disease
of all 1q21.1 rearrangements [16]. Both the proximal and
distal deletions and duplications have been observed in
healthy control cohorts, so all rearrangements of 1q21.1
exhibit incomplete penetrance, although undiagnosed
more subtle phenotypes may be present.
Source of phenotypic variability
TAR syndrome provides an illustration of the challenge
of interpreting rare and large copy number variants. The
genetic heterogeneity underlying TAR syndrome appears
to be limited, yet in addition to the three essential
features of TAR, a wide range of additional phenotypes
can be observed. This begs the question of what accounts
for the phenotypic variability observed in TAR syn-
drome. One possibility is that it is simply variation inCurrent Opinion in Genetics & Development 2013, 23:316–323
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Figure 3
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Microdeletions and duplications of 1q21.1 are associated with a wide range of phenotypes. TAR syndrome is associated with proximal deletions of
1q21.1 (see also Figure 1). Distal 1q21.1 deletions and duplications are associated with microcephaly or macrocephaly [40,41], schizophrenia [38,39],
and a spectrum of developmental delay, neuropsychiatric abnormalities, and dysmorphic features and congenital anomalies [16,35,37,40,42] but are
not associated with a specific syndrome [42]. The approximate breakpoints of the proximal and distal deletions and duplications are indicated by the
gray backgrounds. Segmental duplications (SDs) longer than 1 kb are shown, with SDs with more than 98% sequence similarity shown in orange. The
region contains many SDs and sequence gaps. Note that what was previously known (in build hg18) as the distal 1q21.1 deletion/duplication region
partially overlaps 1q21.2 in the UCSC browser of build hg19. (a) The smallest deletion observed in a TAR patient [46] includes RBM8A. (b) This
atypical 200 kb TAR deletion was identified in a 2007 study of 30 TAR patients [15] and was used to identify RBM8A as the gene underlying TAR
syndrome in 2012 [17]. (c) Typical TAR deletion observed in 28 of 30 TAR patients in the 2007 study [15]. (d) A range of deletions and duplications
was observed in two 2008 studies of the 1q21.1 region [40,42]. The ‘class I’ and ‘class II’ terminology is taken from Ref. [40]. (e) Recently, proximal
duplications in the TAR region in the absence of distal rearrangements were found to be weakly associated with the development of abnormal
phenotypes [16,46].gene expression, which may be further modified by
environmental factors and statistical chance [47] that
accounts for the variability in phenotypes associated with
TAR. Subtle variations in activity of an essential gene of
which a complete knockout is incompatible with devel-
opment may result in a range of malformations. Alterna-
tively, it is possible that further modifier alleles on the
nondeleted chromosome account for the variability, in-
cluding epigenetic alleles. For instance, the cow-milk
allergy and cardiac anomalies frequently observed in
TAR patients have also been observed in individuals
referred for cytogenetic testing found to carry a proximal
1q21.1 deletion but without TAR syndrome [46]; this
could be a consequence of incomplete penetrance of the
TAR mutations (noncoding variant combined with a null
allele) or of the existence of additional modifier alleles in
the proximal 1q21.1 region in genes other than RBM8A.
Interestingly, a sex-bias has been frequently reported for
TAR with an increased incidence in females (ratios varyCurrent Opinion in Genetics & Development 2013, 23:316–323 from 1:1.5 to 1:3.8, see Ref. [48] for an overview). A
detailed study of how the severity of the TAR phenotype
(skeletal abnormalities and thrombocytopenia) and the
range of additional phenotypes in TAR correlate with the
genotype of each individual patient would be of interest.
TAR shows that even relatively high-frequency variants
can have strongly deleterious effects when combined
with a rare deletion. It cannot be excluded that similar
effects can be identified for other genes in 1q21.1.
Although precedent for a noncoding functional SNP
modifying a deletion phenotype had been reported for
Sotos syndrome and factor XII deficiency [49], modifier
alleles and two locus models, distinct from the Knudson
second hit somatic event model [50], have recently
attracted increasing attention [51–53]. Coding variants
in the COMT gene on the nondeleted allele of individ-
uals carrying a 22q11.2 allele can affect cognitive function
[54,55]. Girirajan et al. demonstrated that a second largewww.sciencedirect.com
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phenotypic variability in patients with developmental
disorders [56]. At the cystic fibrosis locus, an upstream
di-nucleotide repeat can modulate exon 9-skipping of the
CFTR gene, but only when activated by the T5 allele of
the polymorphic polythymidine tract in the 30 splice site
of exon 9 [57]. This explains the incomplete penetrance
of the T5 polymorphism [58], analogous to noncoding
SNPs explaining the incomplete penetrance of the 1q21.1
deletion in TAR syndrome.
Whole-genome high-throughput sequencing can simul-
taneously detect copy number variation and noncoding/
regulatory small variants that act as modifiers. Although
this will require large sample sizes, it may prove a way
forward to dissect the phenotypic variability associated
with copy number variation in rare disorders. With anno-
tation of noncoding regions [59] becoming increasingly
richer through large collaborative efforts such as the
ENCODE Project [59], and in particular the BLUE-
PRINT Project [60], which focuses on creating a highly
detailed epigenetic annotation of hematological cell
types, interpretation of additional causative alleles that
do not affect protein-coding sequence but instead affect
gene expression has become feasible. The annotation of
gene expression patterns in different cell types and
developmental stages should provide insight into possible
developmental aspects associated with the noncoding
mutations involved in TAR syndrome. Finally, integ-
ration with the data from large genome-wide association
studies of platelet parameters [61] may provide further
insights into downstream effects of Y14 deficiency on
platelet function.
Conclusion
TAR syndrome is caused by the compound (bi-allelic)
inheritance of one of two noncoding single-nucleotide
variants and a rare null allele in RBM8A. The two
noncoding variants, located in the 50UTR and first
intron, explain the incomplete penetrance of the prox-
imal 1q21.1 deletion and this new insight into the
inheritance pattern will benefit diagnostic testing as
well as counseling. The complex inheritance pattern
ultimately results in reduced expression of Y14, the
protein encoded by RBM8A and a core member of the
exon-junction complex (EJC), in platelets. Further
research is needed to explain how Y14 insufficiency,
and presumably subsequent defect of the EJC, explains
the unique skeletal, hematological and additional fea-
tures of TAR syndrome.
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